Aster Capital Management (Difc) LTD Celldex Therapeutics, Inc. Transaction History
Aster Capital Management (Difc) LTD
- $262 Billion
- Q4 2024
A detailed history of Aster Capital Management (Difc) LTD transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Aster Capital Management (Difc) LTD holds 190 shares of CLDX stock, worth $3,380. This represents 0.0% of its overall portfolio holdings.
Number of Shares
190Holding current value
$3,380% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
198Shares Held
60.8MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$90.1 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$83.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$69.1 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$66.8 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$63.3 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $832M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...